2
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
24
Leukemia, Myeloid, Chronic-Phase
8
Leukemia, Myeloid
3
Leukemia
3
Bronchiolitis Obliterans Syndrome
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Philadelphia Chromosome
2
Myeloproliferative Disorders
2
Recurrence
1
P1b: Advanced Solid Tumors
1
Malignant Solid Tumors
1
Hematologic Diseases
1
HER2+ Metastatic Breast Cancer
1
Burkitt Lymphoma
1
Brain Neoplasms
1
Blast Crisis
1
Advanced Solid Tumors
1
Interventions
Cyclophosphamide
64
Peripheral Blood Stem Cell Transplantation
58
fludarabine phosphate
55
Busulfan
44
Tacrolimus
39
Methotrexate
38
Cytarabine
37
Filgrastim
34
Mycophenolic Acid
33
Cyclosporine
33
Antilymphocyte Serum
32
Whole-Body Irradiation
28
Radiotherapy
25
Methylprednisolone
22
Imatinib Mesylate
22
Etoposide
22
Melphalan
18
Cord Blood Stem Cell Transplantation
18
Flow Cytometry
14
Thiotepa
12
Dasatinib
12
Therapeutics
11
sargramostim
10
merphos
10
fludarabine
10
Sirolimus
10
Granulocyte Colony-Stimulating Factor
10
nilotinib
9
Prednisone
9
Decitabine
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Blast Crisis
×
asciminib
×
Clear all
NCT04877522
2026-05-11
Asciminib Roll-over Study
Novartis
Phase 4
Recruiting
347 enrolled